Status:
UNKNOWN
Clinical Study of Microchimerism and cfDNA as Biomarkers for Acute Rejection After Organ Transplantation
Lead Sponsor:
Fuzhou General Hospital
Collaborating Sponsors:
309th Hospital of Chinese People's Liberation Army
Tianjin First Central Hospital
Conditions:
Organ Transplant Rejection
Eligibility:
All Genders
18-70 years
Brief Summary
Organ transplantation has become an effective therapy for patients with end-stage organ failure at present. Rejection is still the most common cause of early dysfunction after organ transplantation. A...
Detailed Description
Organ transplantation has become an effective therapy for patients with end-stage organ failure at present. Since the launch of pilot voluntary organ donation after death of citizens in 2010, the volu...
Eligibility Criteria
Inclusion
- Single-organ transplant recipients aged above 18 years old Recipients of re-do organ transplants
- Recipients with no systemic acute or chronic infections, infectious diseases;
- Recipients with no severe systemic diseases and/or spiritual system diseases
- Recipients or families signed the consent form.
Exclusion
- Organ transplant recipients whose donor is child (under the age of 18 years old)
- Patients wait-listed for multiple organ transplantation
- Unable or unwilling to follow up regularly
Key Trial Info
Start Date :
March 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
950 Patients enrolled
Trial Details
Trial ID
NCT03255265
Start Date
March 1 2017
End Date
December 31 2021
Last Update
August 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuzhou General Hospital, Xiamen Univ Fuzhou, Fujian China
Fuzhou, Fujian, China, 350025